Predictors of cardiomyopathy in patients with type-2 diabetes mellitus with and without cardiovascular complications: A cross-sectional study

Bashir, Aamir; Azharuddin, .; Rashid, Ishfaq; Murti, Krishna; Pandey, Krishna

doi:10.1016/j.diabres.2019.06.012

Cited by 4 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant difference was found in changes in hs-cTnT/I between non-ST elevation myocardial infarction patients with and without T2DM [79,80]. However, elevated hs-Tnl levels were found to be independent predictors of MACE in individuals with known CAD regardless of glucose metabolism status [46,79,81,82] as well as among patients with prediabetes and T2DM without known CAD [83,84]. Interestingly, in several large clinical trials, such as SAVOR-TIMI 53 and TECOS, elevated levels of hs-cTnT in patients with T2DM during treatment with antidiabetic drugs (inhibitors of dipeptidyl peptidase 4 saxagliptin and sitagliptin) were significantly associated with renal outcomes rather than CV events and MACEs [85,86], but in diabetics with CV disease, i.e., myocardial infarction, the hs-cTnT levels corresponded positively to CV death, MACEs and HF [87].…”

Section: Cardiac Troponinsmentioning

confidence: 99%

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Berezin

2020

Diabetes Ther

View full text Add to dashboard Cite

The aim of this narrative review is to update the current knowledge on the differential choice of circulating cardiac biomarkers in patients with prediabetes and established type 2 diabetes mellitus (T2DM). There are numerous circulating biomarkers with unconfirmed abilities to predict clinical outcomes in pre-DM and DM individuals; the prognostication ability of the cardiac biomarkers reported here has been established, and they are still being studied. The conventional cardiac biomarkers, such as natriuretic peptides (NPs), soluble suppressor tumorigenisity-2, high-sensitivity circulating cardiac troponins and galectin-3, were useful to ascertain cardiovascular (CV) risk. Each cardiac biomarker has its strengths and weaknesses that affect the price of usage, specificity, sensitivity, predictive value and superiority in face-to-face comparisons. Additionally, there have been confusing reports regarding their abilities to be predictably relevant among patients without known CV disease. The large spectrum of promising cardiac biomarkers (growth/differential factor-15, heart-type fatty acid-binding protein, cardiotrophin-1, carboxy-terminal telopeptide of collagen type 1, apelin and noncoding RNAs) is discussed in the context of predicting CV diseases and events in patients with known prediabetes and T2DM. Various reasons have been critically discussed related to the variable findings regarding biomarker-based prediction of CV risk among patients with metabolic disease. It was found that NPs and hs-cTnT are still the most important tools that have an affordable price as well as high sensitivity and specificity to predict clinical outcomes among patients with pre-DM and DM in routine clinical practice, but other circulating biomarkers need to be carefully investigated in large trials in the future.

show abstract

Section: Cardiac Troponinsmentioning

confidence: 99%

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Berezin

2020

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…Type 2 diabetes (T2D) is a major risk factor for cardiovascular events and has been linked to some cardio-metabolic risk factors such as obesity, hypertension, and dyslipidemia [1]. Cardiac complications of diabetes include cardiomyopathy, ischemic heart diseases, left ventricular dysfunction, heart failure, and arrhythmias [2,3]. In the presence or absence of microvascular or macrovascular problems, several studies revealed that T2D causes electrocardiogram abnormalities.…”

Section: Introductionmentioning

confidence: 99%

Cardiometabolic risk factors and electrocardiogram results in type 2 diabetes patients with or without non-infected foot ulcers: A comparative study

Al-Nimer

Ratha

2023

Diabetes mellitus

View full text Add to dashboard Cite

BACKGROUND: Numerous investigations have demonstrated that type-2 diabetes (T2D) causes electrocardiographic alterations, whether or not there are microvascular or macrovascular problems.AIM: With respect to glycemic control and the accompanying cardio-metabolic risk factors, the goal of this study was to demonstrate the variations in electrocardiogram records between T2D patients with non-infected diabetic foot ulcers (DFUs) and those without ulcers.METHODS: This study was performed in the Shar Teaching Hospital in the Sulaimani Governorate-Iraq from July 2018 to June 2019. 167 participants were grouped into Group I (T2D, n=72); Group II (T2D with non-infected diabetic foot ulcers, n=65) and Group III (healthy subjects, n= 30). Blood pressure, electrocardiography, and anthropometric measurements were taken. Fasting serum glucose and lipid profiles were assessed as part of laboratory tests.RESULTS: Group II patients significantly differed from Group I by having lower diastolic blood pressure, a higher pulse pressure index, and a higher fasting serum glucose. The Group I patients had a significantly higher heart rate, a shortening of TQ-interval and widening of QRS dispersion. Group II patients had a significantly shorter TQ-interval compared with the corresponding value of Group I patients (523.6±136.4ms versus 579.2±110.0ms, respectively). These changes in the electrocardiograms are not related to the cardiometabolic risk factors.CONCLUSION: In the non-infected diabetic foot, the TQ-interval, a measure of ventricular repolarization impairment, is much shorter and is linked to a broad pulse pressure. According to this finding, the electrocardiographic abnormalities are a result of cardiovascular autonomic dysfunction.

show abstract

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

et al. 2020

View full text Add to dashboard Cite

Predictors of cardiomyopathy in patients with type-2 diabetes mellitus with and without cardiovascular complications: A cross-sectional study

Cited by 4 publications

References 42 publications

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review

Cardiometabolic risk factors and electrocardiogram results in type 2 diabetes patients with or without non-infected foot ulcers: A comparative study

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

Contact Info

Product

Resources

About